Two bulls weigh in believing short-term financing pressure on SGYP stock will lessen with the funding reveal.
BTIG’s Tim Chiang says Synergy has a “differentiated product” on its hands compared to the current winning market player: Ironwood/Allergan’s Linzess.
Canaccord’s John Newman finds SGYP’s Trulance commercial potential enticing down the line against its competitors.
Now that SGYP has won over FDA approval in a new indication (IBS-C), did the biotech company’s competitive edge just get sharper?
Ahead of the fourth quarter showcase from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) anticipated March 7th, first comes a PDUFA date of FDA judgment for …
H.C.
As SGYP and PGNX both await potential FDA approvals this year, BTIG’s Tim Chiang shares his positive two cents on these drug makers he believes present meaningful upside potential.
Risk-taker Dmitry Balyasny eyes advantage in the biotech world, between new initiations in TEVA, SGYP, and a major increase in OPK.
